H. Lundbeck

CNS-focused pharma

HLUN.B · Nasdaq Copenhagen · Denmark

Public Market Listing

HLUN.BNasdaq Copenhagen

Nasdaq Copenhagen primary exchange listing

Live quotes, historical charts, and market capitalization for H. Lundbeck are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(10 total)
10Total Assets
8Approved
1Phase 3 / Filed
1Phase 1–2 / Early
10Diseases
Quick filter:
Showing 10 of 10 assets
Target & Modality
Approved
Dopamine D2 and serotonin 5-HT1A receptors (partial agonist) · Dopamine D2/D3 and serotonin 5-HT1A receptor · Dopamine D2 receptor (partial agonist)Small molecule
SchizophreniaBipolar Disorder
Approved
Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule
Major Depressive DisorderSchizophreniaBipolar Disorder
Approved
Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule
Alzheimer's DiseaseMajor Depressive DisorderSchizophrenia
Approved
GABA-A receptorSmall molecule
EpilepsyDevelopmental and Epileptic EncephalopathiesLennox-Gastaut Syndrome
Approved
norepinephrine precursorSmall molecule
Parkinson's DiseaseNeurogenic Orthostatic Hypotension
Approved
CGRP ligandMonoclonal antibody
Migraine
Approved
GABA transaminase (GABA-T)Small molecule
EpilepsyDevelopmental and Epileptic Encephalopathies
Focal Onset Seizures
Vortioxetine(Trintellix)
Approved
Serotonin transporter + multiple 5-HT receptorsSmall molecule
Major Depressive Disorder
Phase 3
Serotonin 5-HT2C receptor (agonist)Small molecule
Epilepsy
Phase 2
D1/D2Small molecule
Parkinson's Disease

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
BexicaserinPhase 3Dravet Syndrome
Est. primary completion 2026-12-31 · NCT06660394 · CT.gov ↗
What to watch
2027 (4)
March 2027 (1)
Eptinezumab (Vyepti)Phase 3Chronic Migraine in Children
Est. primary completion 2027-03-26 · NCT04965675 · CT.gov ↗
What to watch
July 2027 (1)
Eptinezumab (Vyepti)Phase 3Episodic Migraine
Est. primary completion 2027-07-06 · NCT05897320 · CT.gov ↗
What to watch
September 2027 (1)
Brexpiprazole (Rexulti)Phase 3Acute Schizophrenia
Est. primary completion 2027-09 · NCT05325645 · CT.gov ↗
What to watch
November 2027 (1)
BexicaserinPhase 3Developmental and Epileptic Encephalopathy
Est. primary completion 2027-11-11 · NCT06908226 · CT.gov ↗
What to watch
2028 (2)
April 2028 (1)
Eptinezumab (Vyepti)Phase 3Migraine
Est. primary completion 2028-04-30 · NCT05164172 · CT.gov ↗
What to watch
October 2028 (1)
Lu AF28996Phase 2Parkinson's Disease
Est. primary completion 2028-10-03 · NCT07514858 · CT.gov ↗
What to watch
2029 (1)
September 2029 (1)
Vortioxetine · TrintellixPhase 3Major Depressive Disorder
Est. primary completion 2029-09-30 · NCT07204314 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

16 September 2026ApprovalEptinezumab (Vyepti)Japan grants marketing authorisation for eptinezumab
JP, MHLW · H. Lundbeck A/S · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q4————report ↗